The effect of Mito-Tempo on IL-17/IL-23 signaling suggests a novel mechanism whereby mtROS modulates CD inflammation via IL-17/IL-23, the targeting of which by mirikizumab or guselkumab was recently reported to have benefits in phase 2 clinical trials for CD [44,48]. This evidence concerns the gene IL23A and Cowden disease.